



## Rapifen advertisement.

[s.l.]: [s.n.], 1984

<https://digital.library.wisc.edu/1711.dl/Z6KT4QSSHDPD38K>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



# At last, rapid analgesia with rapid recovery.

*New*

Trademark

**RAPIFEN**

(alfentanil)

minute by minute control of short procedures

**Prescribing Information** **Presentation** Clear, colourless, aqueous injection, containing 500µg/ml alfentanil hydrochloride, in 2ml ampoules. **Uses** Analgesic adjunct to anaesthesia in short operative procedures and outpatient surgery, requiring spontaneous respiration. Rapifen may also be administered to ventilated patients undergoing longer operative procedures (see data sheet). **Dosage** (Spontaneous respiration in adults) Initial: Up to 500 (1ml). This should be given by slow i.v. injection over about 30 seconds. Supplemental: Up to 250µg (0.5ml) every 4-5 minutes or sooner if the patient exhibits signs of insufficient analgesia. Anticipation of surgical stimulation is helpful. **Contra-indications, warnings etc.** Contra-indications: Obstructive airways disease or respiratory depression if not ventilating. Administration with MAOI's or within two weeks of their discontinuation. Administration in labour or before clamping of the cord during Caesarian section. Warnings: May produce a transient fall in blood pressure. Doses in excess of 1000µg (2ml) will produce significant respiratory depression, usually short duration. This can be reversed with naloxone (0.1-0.2mg i.m. or i.v.). Bradycardia may occur and can be antagonised by atropine. Muscular rigidity (morphine-like effect) may occur and can be helped by muscle relaxants. Concurrent administration with other narcotic or CNS-depressant drugs can be expected to be additive in effect. **Precautions** Reduce dosage in the elderly, in hypothyroidism and in chronic liver disease. **Side effects** Nausea, vomiting and dizziness have been reported. **Use in pregnancy** Safety in humans has not been established. Risk should be weighed against potential benefit. **Overdosage** Symptoms should be treated indicated in the "Warnings" section above. General supportive measures should also be employed. **Pharmaceutical precautions** Combinations with alkaline agents should be avoided. **Basic NHS cost** 2ml x 10 ampoules: £7.43. Product licence number 0242/0091. Further information is available from the product licence holder: Janssen Pharmaceutical Ltd., Janssen House, Chapel Street, Marlow, Bucks. SL7 1ET. © JPL/81/83